MDxHealth heads into the post-earnings session with a sharply lower stock, a revenue miss, and a guidance cut that wiped nearly a fifth off the full-year sales outlook in a single statement.
The results, released after the close on May 13, were blunt. Q1 EPS came in at -$0.17, missing the -$0.12 consensus by five cents. Revenue of $27.4 million trailed the $30.6 million estimate. Worse, management slashed FY2026 sales guidance from a $137–140 million range to $110–115 million — a reduction of roughly $25 million at the midpoint, against a Street estimate of $135.9 million. The stock had already fallen 6% on the day to $1.87, down 8.3% over the past month and near its lowest level of the three-month period.
Short positioning ahead of the print was telling, though the absolute level remains minor. Estimated short interest jumped 160% week-on-week to around 51,000 shares, lifting SI as a percentage of free float to roughly 0.14%. That's a sharp proportional move, but the absolute level — well under 1% of the float — means there is no meaningful short overhang and no squeeze mechanics in play. Borrow availability is deep: the lending pool is barely drawn upon, and the cost to borrow at 6.2% has barely budged, up less than half a percent on the week. The borrow market is not signalling any stress. What the jump in short shares does reflect is a small cluster of traders positioning for a weak print — a bet that proved directionally correct.
The Street has been broadly constructive on MDXH, but analyst data is now dated. The most recent changes on record are from late 2025, when BTIG, TD Cowen, and Lake Street all reiterated or raised Buy ratings with targets in the $7–9 range, following what was then a more optimistic growth trajectory. Those targets carry a caveat: they predate tonight's guidance cut by six months, and the mean target of $7.40 sits roughly 4x above the current price of $1.87. That gap will almost certainly narrow once analysts update models to reflect the revised $110–115 million revenue range. The EV/EBITDA multiple has compressed nearly 3 points over the past 30 days — the valuation was already being re-rated lower before tonight.
Institutional ownership is concentrated. Bleichroeder LP holds 14.4% of shares, AWM Investment Company a further 10.2%, and MVM Partners 9.2%, meaning fewer than five holders collectively represent over a third of the register. Abbott Laboratories added its entire 4.75% position as recently as January 2026 — the only meaningful new institutional entry in recent filings. That concentration can amplify moves when the stock dislocates, as fewer natural sellers are needed to move the price. Most of the top holders showed no change in their last reported period, suggesting no pre-announcement repositioning at the institutional level.
The one historical reference point available from earnings history shows a -3.7% one-day move and a -6.2% five-day move following the February 2026 earnings release. The Q1 2026 print delivered a larger revenue shortfall and a guidance cut that dwarfs anything in recent quarters, so that prior reaction only serves as a floor reference rather than an anchor. The ORTEX short score of 29.5 is modest and has barely moved over the past two weeks, consistent with the low absolute short interest. Closest Nasdaq peers AVXL fell 5.6% on the day and RXRX dropped 3.4%, suggesting broader sector weakness added pressure alongside the company-specific miss.
What to watch next: the key question coming out of the May 13 call is the degree to which management articulates a credible path back to the original revenue trajectory — and whether any of the four analysts who held Buy ratings through February maintain those positions after revising models for the new $110–115 million sales range.
See the live data behind this article on ORTEX.
Open MDXH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
